Dalotuzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Dalotuzumab
Accession Number
DB11840
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • MK-0646
Categories
UNII
6YI1L648RH
CAS number
1005389-60-5

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Dalotuzumab.
AbituzumabThe risk or severity of adverse effects can be increased when Dalotuzumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Dalotuzumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Dalotuzumab.
AducanumabThe risk or severity of adverse effects can be increased when Dalotuzumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Dalotuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dalotuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Dalotuzumab.
AmatuximabThe risk or severity of adverse effects can be increased when Dalotuzumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Dalotuzumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911246
Wikipedia
Dalotuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentCancer, Breast2
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentMultiple Myeloma (MM) / Tumors, Solid1
1CompletedTreatmentNeoplasms2
1CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentTumors, Solid1
1TerminatedTreatmentNeoplasms Malignant1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Pancreas / Malignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentCancer, Breast1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2CompletedTreatmentMetastatic Colorectal Cancers1
2CompletedTreatmentMetastatic Neuroendocrine Tumors / Neuroendocrine Tumors1
2CompletedTreatmentRectal Neoplasms1
2TerminatedTreatmentNeoplasms, Breast1
2WithdrawnTreatmentLung Cancers1
2WithdrawnTreatmentMetastatic Colorectal Cancers1
Not AvailableNot Yet RecruitingNot AvailableCancer of the Ovary1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:52 / Updated on November 02, 2018 07:16